Literature DB >> 29662276

Comparison Between Use of Oral Misoprostol Versus Vaginal Misoprostol for Induction of Labour at Term.

Kavya D Sharma1.   

Abstract

BACKGROUND AND
OBJECTIVE: In modern obstetrics, around 30% of cases require induction of labour for various reasons. Misoprostol is gaining popularity as pharmacological inducing agent, though the route and dosage of administration are not standardised. The objective of the study is to compare the safety and efficacy of the two routes of misoprostol administration-oral (100 μg 4th hourly) and vaginal (25 μg 4th hourly), for induction of labour at term.
METHODS: In this randomised trial, 104 women having crossed the expected date of delivery without going into spontaneous labour and cases which had premature rupture of membranes <12 h were considered for labour induction and were divided into two equal groups. Group A received 100 μg misoprostol orally 4th hourly, and group B received 25 μg misoprostol vaginally 4th hourly. Labour characteristics and maternal and foetal outcome were compared.
RESULTS: In terms of maternal outcome, mean number of doses for oral group is 2.73 and vaginal group is 3.04. In oral group, mean induction to vaginal delivery interval was 13 h 43 min and in vaginal group interval is 13 h 26 min which was statistically not significant. The need for oxytocin augmentation was also statistically not significant. Both groups had equal number of failed inductions. Emergency LSCS done for foetal distress was more in vaginal group 2.9% compared to oral group which is 1%, but difference was not statistically significant (p value -0.55). Number of thick MSL in oral group was 3.2% as compared to vaginal group which is 10.7% which was statistically significant (p value -0.04). APGAR score at 5 min 7/10 was seen in 7.7% in vaginal group as compared to 0% in oral group which was also statistically significant (0.004). Number of NICU admissions was also more in vaginal group compared to oral group.
CONCLUSION: Misoprostol in either oral or vaginal route has proven to be equally effective for inducing labour in women at term pregnancy. However, occurrence of lesser incidence of meconium-stained liquor and NICU admissions and fewer caesareans with better neonatal outcome in women induced with oral misoprostol outweighs its advantages over the vaginal misoprostol.

Entities:  

Keywords:  Induction; Misoprostol; NICU; Pregnancy

Year:  2017        PMID: 29662276      PMCID: PMC5895553          DOI: 10.1007/s13224-017-0978-3

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  6 in total

1.  Oral versus vaginal misoprostol for induction of labor in Enugu, Nigeria: a randomized controlled trial.

Authors:  Paschalina Constance Ezechukwu; Emmanuel Onyebuchi Ugwu; Samuel Nnamdi Obi; Chibuike Ogwuegbu Chigbu
Journal:  Arch Gynecol Obstet       Date:  2014-08-20       Impact factor: 2.344

2.  A comparison of oral and vaginal misoprostol for induction of labor.

Authors:  Seyfettin Uludag; Funda Salihoglu Saricali; Riza Madazli; Ismail Cepni
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-09-01       Impact factor: 2.435

3.  Comparative study of efficacy and safety of oral versus vaginal misoprostol for induction or labour.

Authors:  Varsha Laxmikant Deshmukh; Kanan Avinash Yelikar; Vandana Waso
Journal:  J Obstet Gynaecol India       Date:  2013-05-03

4.  Comparative study of oral and vaginal misoprostol for induction of labour, maternal and foetal outcome.

Authors:  Kambhampati Komala; Meherlatha Reddy; Iqbal Jehan Quadri; Suneetha B; Ramya V
Journal:  J Clin Diagn Res       Date:  2013-12-15

5.  Safety and efficacy of oral versus vaginal misoprostol use for induction of labour at term.

Authors:  Razia Mustafa Abbassi; Pushpa Sirichand; Sadaf Rizvi
Journal:  J Coll Physicians Surg Pak       Date:  2008-10       Impact factor: 0.711

6.  Oral versus vaginal misoprostol for labour induction.

Authors:  Rozina Rasheed; Azra Ahsan Alam; Shehnaz Younus; Farahnaz Raza
Journal:  J Pak Med Assoc       Date:  2007-08       Impact factor: 0.781

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.